|With the help of patient groups, biotechs hone in on rare diseases|
The approach it takes to drugs is focused on turning off specific disease-causing genes, and it has one drug in development for cancers and another for a rare form of hyperoxaluria (too much oxylate in the urine). "It's the best application of our ...
Boston Business Journal (blog) - Thu, 26 Feb 2015 11:23
|Dicerna Pharmaceuticals Announces Move to Larger Office and Lab Space in ...|
In 2015, Dicerna will start clinical development of a second innovative medicine, DCR-PH1, which has the potential to be a functional cure for the serious and difficult-to-treat genetic disease primary hyperoxaluria type 1 (PH1). Dicerna is currently ...
Business Wire (press release) - Thu, 26 Feb 2015 04:22
|Alnylam Aims to Release Multi-program Clinical Data in 1H 2015|
The company, which also posted its fourth quarter 2014 financial results, further disclosed that it aims to begin human studies for its hepatic porphyria treatment ALN-AS1 and to select a development candidate for its program in primary hyperoxaluria ...
GenomeWeb - Fri, 13 Feb 2015 06:24
|Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2014 Results ...|
Seeking Alpha (registration) - Thu, 12 Feb 2015 20:15
|Alnylam Pharmaceuticals Reports Fourth Quarter and Full Year 2014 Financial ...|
Business Wire (press release) - Thu, 12 Feb 2015 13:00
|Allena Pharmaceuticals Secures $25 Million Series B Financing|
“The positive response and level of interest we have received from investors is a great reflection of our seasoned management team, the market opportunity and the unmet need that ALLN-177 meets in the treatment of hyperoxaluria,” said Alexey Margolin, ...
Business Wire (press release) - Thu, 04 Dec 2014 04:00
|Biotech partners at Allena fund a march toward PhIII with $25M venture round|
FierceBiotech - Thu, 04 Dec 2014 05:53
|Poster Highlights Rapid and Durable Effect of DCR-PH1 in Mouse Model of PH1|
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, presented data from its preclinical program in primary hyperoxaluria type 1 (PH1) in a poster session at the ...
Business Wire (press release) - Tue, 14 Oct 2014 14:22
|A London experience 1995-2012: Demographic, dietary and biochemical ...|
The prevalence of low urine volume, hypercalciuria, hyperoxaluria, hyperuricosuria and hypocitraturia was 5.6%, 38%, 7.9%, 18% and 23%, respectively. The prevalence of several risk factors for stones increased over time. The majority of stones were ...
UroToday - Thu, 26 Feb 2015 18:17
|Researchers Demonstrate Promise of Dicerna Investigational Therapy in ...|
... Inc. (NASDAQ:DRNA), a leader in the development of RNAi-based therapeutics, today announced the presentation of preclinical data demonstrating the promise of DCR-PH1, the Company's therapeutic candidate for the treatment of primary hyperoxaluria ...
Business Wire (press release) - Mon, 30 Jun 2014 05:00
|Why Dicerna Pharmaceuticals Inc Stock Skyrocketed|
Motley Fool - Mon, 30 Jun 2014 14:01
|The Latest Discovery by Dicerna Pharmaceuticals (NASDAQ:DRNA)|
Stocks.org - Tue, 01 Jul 2014 20:33
|Dicerna Pharmaceuticals Flying After Positive Pre-Clinical Data On PH1|
Bidness Etc - Mon, 30 Jun 2014 12:07
|OxThera Initiates Clinical Trial in Primary Hyperoxaluria|
OxThera AB, a Stockholm-based privately-held biopharmaceutical company, today announced that it has initiated a clinical study in in Primary Hyperoxaluria. This announcement bolsters the Company's position as a leader in developing therapies for ...
PR Newswire (press release) - Wed, 08 Jan 2014 00:31